anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The overall goal of the proposed research project is to increase uptake of long-acting reversible contraceptives (LARCs) among clients who receive a safe abortion at a Marie Stopes International - Nepal (MSI-N)/ Sunaulo Parivar Nepal (SPN) centre using a behaviourally-informed intervention: monthly feedback to service providers comparing their LARC uptake as a percentage of PAFP uptake performance to other centres. The impact of the intervention will be evaluated using a clustered, stepped wedge randomized controlled trial (RCT). The intervention will be implemented and data will be collected regularly from 36 centres over a period of 6 months. The RCT study design is stepped wedge, meaning that all health centres will begin in the control group and will be randomly assigned to begin receiving the treatment in 4 "steps". Each step will be 1 month in duration. The primary outcome of interest is LARC uptake as a percentage of PAFP uptake. The secondary outcome is type of method selected. The intervention consists of a monthly poster that centres will receive which shows service providers the PAFP LARC % performance at their centre as compared to 3 similar centres. The intervention was developed using a behavioral science methodology, including interviews with clients and service providers at 9 health centres and user-testing of the intervention with service providers at 4 health centres. Data used for this study will consist of daily PAFP LARC uptake data that is already being collected and consolidated at centres. The data will be securely shared between centres and the MSI-N central support office in Kathmandu on a weekly basis. Data will be securely shared between MSI-N and ideas monthly. Monitoring will consist of mystery client visits at each centre two times during the study period. At least one interview will be conducted with each service provider through the study period. The investigators will manually check 5% of all medical records to confirm that electronic data is accurate. Service providers will undergo written consent in order that they may choose to participate, or choose not to participate, in the study. Individual clients will be opted in to having their data shared for the purpose of the study. Clients will be notified about data sharing through posters and interactions with service providers and can choose not to have their data shared. All safe abortion clients, aged 18 and older, are eligible to have their data shared. Data from approximately 12,000 safe abortion clients will be required for the study. Strict confidentiality procedures in line with Marie Stopes International's best practices will be put into place to ensure that information made public or otherwise distributed outside the PIs and other key personnel cannot be linked to any individual client records. Results from the study will be published in a report, among other outputs, and the outcomes will be shared within MSI as well as with the wider sexual and reproductive health (SRH) community.
Objective: To investigate the efficacy and prognosis of CLAG±DAC (Clofarabine, Cytarabine, G-CSF±Decitabine) chemotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML) . Methods: Continuous cases of R/R AML treated with the CLAG+DAC protocol or CLAG alone at the First Affiliated Hospital of Soochow University from January 2017 to December 2021 were retrospectively analyzed. The baseline characteristics, individual treatment regimen, treatment effect, disease progression, and survival status of patients were recorded. The factors influencing the efficacy of the CLAG±DAC chemotherapy regimens were analyzed, and the overall survival (OS) time after reinduction was calculated using the Kaplan-Meier method. Results: This study included a total of 53 patients, with 33 male patients and an average age of 40.6 years. Thirty-three patients achieved complete remission (CR+CRi) of the disease after the CLAG±DAC chemotherapy regimen and six patients achieved partial remission (PR), while 14 did not. Thirty-two patients eventually underwent hematopoietic stem cell transplantation, and the median OS of the patients was 55.9 months until follow-up. Patients with disease remission after the application of the CLAG±DAC chemotherapy had a significantly longer survival time than those without remission (P<0.001). The results of the multifactorial analysis have revealed that combined DAC (OR=4.60, 95% CI 1.14-23.5, P=0.04) and DNMT3A mutation (OR=0.14, 95% CI 0.01-0.89, P=0.05) were the factors influencing the efficacy of the CLAG±DAC chemotherapy regimen. The remission rate was relatively higher in patients with R/R AML combined with FLT3-ITD mutation by applying the DAC+CLAG regimen (OR=10.84, 95%CI 1.48-288.50, P=0.04) . Conclusion: The CLAG±DAC regimen is considered effective in patients with R/R AML, whereas decitabine combined with the CLAG regimen is more suitable for patients with R/R AML combined with FLT3-ITD mutation.
The invention discloses a day cream and a preparation method thereof and belongs to the field of cosmetics. The day cream contains active ingredients, i.e. glabridin, a pomegranate extract ellagic acid and a cactus extract. The preparation method comprises the following steps of: a, dispersing polyacrylic acid by using deionized water until the polyacrylic acid is completely dissolved, and adding glycerol and triethanolamine into the solution to obtain phase A; b, uniformly mixing glyceryl stearate citrate, sodium stearyl lactate, capric triglyceride, dimethicone, diethylene glycol decanoate, cetostearyl alcohol and olive oil, and heating the mixture to form phase B; c, adding the phase B into the phase A, and after stirring and emulsifying the mixture, homogenizing the mixture; and d, stirring and cooling the product obtained in the step c, adding an essence, the glabridin, the pomegranate extract ellagic acid and the cactus extract into the product, and uniformly mixing the materials to obtain the finished product. The three active ingredients and the other auxiliary materials are best proportioned, so that best skin moisturizing, whitening, brightening and protecting states and effects can be achieved. The preparation method is simple in process, low in cost and suitable for industrial production.
BACKGROUND: The aim of this study was to evaluate evolution of ultra-processed food intake and recurrent weight gain in patients who underwent Roux-en-Y gastric bypass.
MATERIALS AND METHODS: This study is an observational longitudinal study that evaluated patients who underwent metabolic and bariatric surgery at four time points: before surgery and at 3, 12, and 60 months after surgery. Anthropometric and dietary intake data were collected through two 24-h dietary recalls. All foods consumed were classified according to degree of processing. Recurrent weight gain was considered the difference between current weight and nadir weight.
RESULTS: The sample consisted of 58 patients with a mean age of 38.7 ± 8.9 years and 68% female. After 60 months, mean excess weight loss and recurrent weight gain were 73.6 ± 27.2% and 22.5 ± 17.4%. Calorie and macronutrient intake decreased significantly between the pre-surgery period, and 3 and 12 months post-surgery; however, there was no significant difference after 60 months. In relation to food groups or macronutrients, no difference was observed between the pre-surgery period and 60 months post-surgery. The contribution of unprocessed or minimally processed foods to calorie intake gradually decreased after 3 months post-surgery.
CONCLUSION: The profile of dietary intake after 60 months of metabolic and bariatric surgery tends to approach that of the pre-surgery period. The contribution of unprocessed and minimally processed foods to calorie intake decreased after 60 months, while ultra-processed food contribution increased.
No intervention was made in the control group. The women in the control group were called during the 3-month follow-up to ask whether they received treatment for urinary incontinence simultaneously with the telephone calls of the intervention group.
Methods, systems, and software are provided for detecting gene fusions in a subject with a cancer condition through mRNA boundary analysis of next generation sequencing of a transcriptome or relevant part thereof. Methods, systems, and software are provided for detecting splice variants in a subject with a cancer condition through mRNA boundary analysis of next generation sequencing of a transcriptome or relevant part thereof. Methods, systems, and software are provided for evaluating the complexity of an RNA-seq sequencing reaction through mRNA boundary analysis. Generally, the methods described herein include obtaining sequences of mRNA molecules for a plurality of genes in a sample of a subject. For each gene, an RNA boundary distribution including relative abundance value for each respective RNA boundary sub-sequence of the gene is determined from the plurality of sequences. These abundance values are evaluated using one or more models to provide the analyses described herein.
New pharmaceutical preparations for the treatment of cancer types exhibiting excessively high vitamin C concentrations (esp. acute lymphatic leukaemia and bronchial carcinoma) contain as active substance the enzyme ascorbate oxidase, opt. together with usual adjuvants and/or carrier substances. Ascorbate oxidase, which catalyses the aerobic oxidation of ascorbic acid to dehydroascorbic acid, occurs in various plants and can be isolated e.g. by the method of Eur.J.Biochem. 1979, 101, 65-76. Instead of the complete enzyme, the preparations may contain enzymatically active subunits of ascorbate oxidase. The preparations may also contain natural or synthetic substances or compounds having ascorbate oxidase-like activity. The dosage used is dependent on the ascorbate concn. in the cancer tissue.
Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
Colony-stimulating factor 2 (CSF2) plays a regulatory role in numerous cancers. However, there is needed to investigate the role of CSF2 in oral squamous cell carcinoma (OSCC) malignant phenotype and the specific mechanisms of CSF2 N-6-methyladenosine (m6A) modification. Therefore, we investigated the regulatory mechanism of m6A-modified CSF2 by WT1-associated protein (WTAP) in OSCC via qRT-PCR, western blot, WTAP and CSF2 overexpression in OSCC. In a panel of OSCCs, Kaplan-Meier plot analysis indicated that high expression of CSF2 was associated with poorer prognosis. Cell functional experiments revealed that enrichment of CSF2 promoted the proliferation and migration of OSCC cells by activating the JAK/STAT3 pathway, whereas the reduced expression of CSF2 resulted in the malignant decline of OSCC cells by blocking the JAK/STAT3 pathway. This study also confirmed that WTAP enhanced the m6A level of CSF2 and facilitated the expression of CSF2 and that CSF2 silencing blocked the invasive phenotype of OSCC cells and reversed the malignancy induced by WTAP overexpression. Overall, this study demonstrated that WTAP mediates the m6A modification of CSF2 and the JAK/STAT3 pathway, which plays an oncogenic role in the development of OSCC and can be a target for the treatment of patients with OSCC.
FIELD: medicine. SUBSTANCE: composition has water, bioadhesive polymer as a wetting agent and, preferably, a thickening agent. Bioadhesive component consists of macroparticles or fibers of water-swelling but water-insoluble structurized carboxy-functional polymer containing: multiple repeating links 80% of which have at least one carboxyl functional group and about 0.05-1.5% cross-linking agent which does not contain polyalkenyl polyester mainly. Thickening agent is a water-soluble or water-dispersed anionogenic or nonionogenic polymer. The indicated composition is subjected for contact with fabric to be wetted for sufficient time. Composition exhibits prolonged effect and comfort action being applied on body. EFFECT: improved method of wetting, improved quality and property. 57 cl, 3 dwg
PURPOSE OF REVIEW: Identifying patients with risk of developing progressive chronic kidney disease (CKD) early is an important step in improving kidney care. This review discusses four recently developed models, two which predict risk of new onset disease, and two which predict progression earlier in the course of disease.
RECENT FINDINGS: Several models predicting CKD incidence and progression have been recently developed and externally validated. A connecting theme across these models is the use of data beyond estimated glomerular filtration rate, allowing for greater accuracy and personalization. Two models were developed with stratification by diabetes status, displaying excellent model fit with and without variables like use of diabetes medication and hemoglobin A1C. Another model was designed to be patient facing, not requiring the knowledge of any laboratory values for use. The final model was developed using lab data and machine learning. These models demonstrated high levels of discrimination and calibration in external validation, suggesting suitability for clinical use.
SUMMARY: Models that predict risk of CKD onset and progression have the potential to significantly reduce disease burden, financial cost, and environmental output from CKD through upstream disease prevention and slowed progression. These models should be implemented and evaluated prospectively in primary care settings.
The disclosure relates to methods and systems of providing secure remote health data routing for diagnostics, treatment, monitoring, and/or other health data. The system may use an anonymized identification (ID) token that may protect privacy and ensure security. The ID token may be attached with additional data such as electronic medical record (EMR) data. As such, the system may digitize and securely transmit EMR data to appropriate constituents. The system may apply routing rules and routing tables to identify the appropriate constituents. The system may also route the EMR data for storage at a user's personal device, which may include a chip card or a user device. As such, the user's personal device may store an EMR based on the EMR data, including proof of health, such as vaccination, and other health data relating to the user.
The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
The invention provides a Chinese medicine preparation for treating coronary heart disease. The Chinese medicine preparation is prepared from the following Chinese medicine materials: caulis polygoni multiflori, notoginseng, radix salivae miltiorrhizae, drachonis sanguis, semen boitae, eupolyphaga, rhizoma ligustici wallichii, cassia twig, herba leonuri, radices paeoniae alba, astragalus root, codonopsis pilosula, pseudostellariae, corydalis tuber, radices saussureae, borneol, cortex albizziae, magnolia hypoleuca, radix angelicae formosanae, rhizoma cyperi, radices polygoni multiflori, scorpion, rhizoma sparganii, rehmannia glutinosa, rhizoma anemones altaicae and polygala. The Chinese medicine preparation uses traditional Chinese herbal medicines as raw materials and is prepared through a scientific formulation and repeated validation of clinical test. The Chinese medicine preparation uses methods such as activating blood, removing stasis, dredging collaterals, opening orifices, restoring yang, rescuing collapse, replenishing qi, returning yang and the like to make the medicine directly reach focus. The Chinese medicine preparation improves coronary blood flow, strengthens the content of myocardial oxygen to increase requirement of myocardium on blood and reaches the activity of dredging coronary artery vessel wall to increase elasticity of coronary artery. The drug has the advantages of no toxicity, no side effect, high radical curing efficiency, low treatment expense and short treatment course.
Provided are various embodiments relating to caninized TNFÎ± antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain.Provided are various embodiments relating to caninized TNFÎ± antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain. Methods, systems, and devices for wireless communication are described. In one example, an aerial user equipment (UE) may receive an indication of a priority for cell selection for aerial UEs from each cell in a set of cells and may select a cell from the set of cells based on the priority of each cell in the set of cells. In another example, an aerial UE may connect to a network available to aerial UEs and non-aerial UEs for auxiliary communications, when appropriate. In yet another example, when an aerial UE transitions to a new mission status, the aerial UE may transmit a tracking area update (TAU) if the aerial UE is connected to a cell in a tracking area that does not support the new mission status. In yet another example, a base station may page an aerial UE based on a mission status of the aerial UE.
Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
The Alberta Orthopaedic Society through its Arthroplasty Service Design Working Group has, after carefully reviewing the existing conventional approach to arthroplasty care, developed what they believe could be a much improved new evidence based arthroplasty care model. This model represents how ideally a patient would access and receive health services across the complete continuum of care. In addition, wherever possible, evidence gathered from the literature and from "known best practices" has been utilized to develop standards related to access, wait times, clinical quality, resource use and health outcome measures. Where no evidence or "known best practices" exist, a standard that best support achieving other known standards are being developed. This new evidence based arthroplasty model seeks to significantly minimize and where possible, eliminate all the current gaps and barriers to arthroplasty care.

This study will seek to prove that the new evidence based arthroplasty model will deliver improved patient outcomes with improved cost effectiveness. Once proven, it is anticipated that this new evidence based arthroplasty model will become the standard of care in Alberta, and a model for other jurisdictions to use in their health service re-designs
Subjects inserted with the AtaCor StealthTrac Lead Model AC-1010. This was the first model evaluated in the study.
The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
The use of REMICADE at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. A randomized, double-blind, placebo-controlled study evaluated the use of REMICADE (5 mg/kg or 10 mg/kg at Weeks 0, 2, and 6) in patients with moderate or severe heart failure [New York Heart Association (NYHA) Functional Class III/IV]. Compared to patients who received placebo, there was a higher rate of mortality and a higher risk of hospitalization at Week 28 due to heart failure in patients who received the 10 mg/kg REMICADE dose, and higher rates of cardiovascular adverse events in patients who received REMICADE doses of 5 mg/kg and 10 mg/kg.

There have been post-marketing reports of new onset and worsening heart failure, with and without identifiable precipitating factors (e.g., pre-existing cardiovascular disease), in REMICADE-treated patients. Some of these patients have been under 50 years of age. 

If a decision is made to administer REMICADE (≤ 5 mg/kg) to patients with moderate or severe heart failure or to administer REMICADE (any approved dose) to patients with mild heart failure, they should be closely monitored during therapy, and REMICADE should be discontinued if new or worsening symptoms of heart failure appear [see Contraindications (4) and Adverse Reactions (6.1)].
The crystallohydrate and the method for its production find application in the pharmaceutical industry. They guarantee high purity and yield of the turned out product. By the method, the crystallohydrate of rifamycin is produced by condensation of 3-aminoformylrifamycin SV and 1-amino-4-cyclopentylpiperazine in a medium of tetrahydrofuran in the presence of ascorbic acid. The turned out product is salted out with water, after which it is filtered without cooling, rinsed in water and is dried. The dried product is mixed with 45-50 vol. % of ethanol in the presence of ascorbic acid and is continuously agitated for 4-5 h at 43-47 degrees C in inert atmosphere. The crystalohydrate produced in separated and is dried. 2 claims, 1 figure
In patients with major depressive disorder, various functional areas are impaired, negatively impacting the quality of life. Remission can restore pre-depression functions; however, some patients may still have residual impairments. Distinguishing between near-normal recovery and residual impairment helps identify those at a high risk of relapse risk and helps tailor treatment. Accordingly, we aimed to discover and validate biomarkers that distinguish between near-normal recovery and residual impairment in remission states through serum proteome analysis. Pooled serum and individual serum samples from three groups (depression status, remission status with residual impairment, and remission status with normal recovery) were analyzed using liquid chromatography-tandem mass spectrometry. The combination of four proteins-antithrombin-III, serum amyloid A4 protein, C1q subcomponent subunit B, and serum amyloid P-component-was selected as a candidate biomarker. The trend of protein changes suggests complement C1q subcomponent subunit B and serum amyloid P-component as potential biomarkers for distinguishing remission from residual impairment. Changes in complement C1q subcomponent subunit B and serum amyloid P-component suggest that the complement system and inflammation-related immune mechanisms are associated with residual impairment in remittent major depressive disorder.